Sign in or Sign up

User ID

Password

Remember me - forgot password

 

Sign up or Sign in

Name (in full)

Email address

Password

Confirm Password

 

Atosiban

Overview

Atosiban is a peptide analogue of oxytocin but with oxytocin properties. It has been investigated by IV-inf as a tocolytic in the management of premature labor, but there is some concern about adverse effects on the fetus.

Category:

  • 22 Obstetrics and gynecological preparations
  • 22.1 Labor inducers/inhibitors
  • 22.1.1 Oxytocics

Primary Characterstics

. It is of Synthetic origin. . The Molecular Weight of Atosiban is 994.20.

Pharmacokinetics

Volume of distribution is found to be 18.3±6.8litre and plasma protien binding is 46-48%.

Indications

Atosiban is primarily indicated in conditions like Uncomplicated premature labor.

Contraindications

Interactions

No data regarding the interactions of Atosiban was found.

Interference in Pathology

No data regarding the pathological interferences produced by Atosiban is available.

Side Effects

The symptomatic adverse reactions produced by Atosiban are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Nausea, Vomiting, Fever, Tachycardia, Insomnia, Rashes, Hot flushes, Hyperglycemia, Injection site reactions.

Available Brands

No Brands Available.

Dosage

Atosiban's dosage details are as follows: No data regarding the Adult dosage details of Atosiban is available. No data regarding the Paedriatic dosage details of Atosiban is available. No data regarding the Paedriatic dosage details of Atosiban is available.
Dose Single Dose Frequency Route Instructions
Adult Dosage
Paedriatic Dosage ( 20 Kg. )
Neonatal Dosage ( 3 Kg. )

High Risk Groups

No Information regarding High Risk Group is available.

Warning / Precautions

Monitor blood loss after delivery;Intra-uterine growth retardation; hepatic impairment ,renal impairment

Storage Conditions

infusions

Store in a well closed container, Below 15°C.

comments powered by Disqus